Safety and efficacy of the Russian COVID-19 vaccine: more information needed

Authors:

EBEnrico Bucci
Enrico Bucci
KAKonstantin Andreev
Konstantin Andreev
ABAnders Björkman
Anders Björkman
RCRaffaele Adolfo Calogero
Raffaele Adolfo Calogero
ECErnesto Carafoli
Ernesto Carafoli
PCPiero Carninci
Piero Carninci
PCPaola Castagnoli
Paola Castagnoli
ACAndrea Cossarizza
Andrea Cossarizza
CMCristina Mussini
Cristina Mussini
PGPhilippe Guerin
Philippe Guerin
BLBrian Lipworth
Brian Lipworth
GSGianluca Sbardella
Gianluca Sbardella

Publisher website

1 October 2020

journal article
letter
Published by Elsevier in The Lancet

Vol. 396 (10256) , e53-E53
DOI:10.1016/s0140-6736(20)31960-7
PMID:32971041
PMCID:PMC7503114

Abstract

No abstract available

This publication has 1 reference indexed in Scilit:

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
The Lancet, 2020